Free shipping on all orders over $ 500


Cat. No. M7563
CZ415 Structure
Size Price Availability Quantity
5mg USD 150  USD150 In stock
10mg USD 240  USD240 In stock
50mg USD 920  USD920 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

In vitro: Inhibition of phosphorylation for both downstream targets results in 14.5 nM IC50 for pS6RP and 14.8 nM for pAKT. The immunosuppressive effect of CZ415 is measured by detecting secreted IFNγ after 18 hours in stimulated human whole blood and the resulting IC50 is 226 nM. As a predictor for cardiotoxicity, the activity of CZ415 against the human cardiac ion channel hERG is assessed in a whole-cell patch-clamp assay in HEK293 cells resulting in an IC50 of 48 μM.

In vivo: CZ415 is a highly selective mTOR inhibitor showing in vivo efficacy in a collagen induced arthritis (CIA) model. For full characterization of CZ415 and to enable improved dose predictions, the pharmacokinetic (PK) profile is assessed in rat. PK and oral bioavailability are determined after of 1 mg/kg intravenous (iv) bolus and 3 mg/kg oral (po) administration. The observed plasma clearance, corresponding to 45% liver blood flow, suggests that sufficient levels of free compound are circulating in the animal over time. The oral uptake is rapid with a Tmaxmax of 0.5 h and bioavailability F = 44% indicates very good absorption from the gut.

Cell Experiment
Cell lines HNSCC cell
Preparation method SCC-9 cells (1×104 per 10-cm dish) were originally plated in 0.5% agarose-containing complete medium. After applied CZ415 treatment of 10 days, the survival SCC-9 colonies were manually counted.
Concentrations 100 nM
Incubation time 72 h
Animal Experiment
Animal models nude mice bearing SCC-9 tumors
Dosages 20 mg/kg
Administration gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 459.56
Formula C22H29N5O4S
CAS Number 1429639-50-8
Purity >98%
Solubility DMSO: ≥ 60 mg/mL
Storage at -20°C

[1] Xie J, et al. Cell Physiol Biochem. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.

[2] Li X, et al. Cell Physiol Biochem. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.

Related mTOR Products
MTI-31 (LXI-15029)

MTI-31 (LXI-15029) is a novel low-toxicity mTORC1/mTORC2 inhibitor, demonstrated a potent mTOR binding affinity with >5000 fold selectivity over the related PI3K family isoforms. MTI-31 inhibited mTORC1- and mTORC2 function at ≤120 nM in cellular assays.

mTOR inhibitor-1

mTOR inhibitor-1 is a potential ATP-competitive inhibitor of mTOR which could inhibit cell growth and proliferation.


L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

LY303511 hydrochloride

LY303511 hydrochloride is a structural analogue of LY294002. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors.


MHY1485 is an mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.

Abmole Inhibitor Catalog 2017

Keywords: CZ415 supplier, mTOR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.